Kobe University · Graduate School of Health Sciences · 教授

Research keywords免疫組織化学・腫瘍病理学・細胞診・骨代謝・膵癌・外泌体

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• カルシウム欠乏卵巣摘出マウスを用いたミネラル投与による骨代謝への影響評価2025 · 2025年06月, Functional Food Research, 21, 144 - 151, 日本語
• 卵巣摘出マウス大腸における細胞増殖・細胞死関連蛋白の発現2024 · 2024年04月, 神戸常盤大学紀要, 17, 46 - 53, 日本語
• Clinicopathological Analysis of DU-PAN-2 as a Tumor Marker for Endometrial Adenocarcinoma in Comparison with CA19-9 :2022 · We investigated the clinical and immunohistochemical availability of DU-PAN-2 (sialyl Lewis^c) as a tumor marker for endometrial adenocarcinomas (EMACs) in comparison with that of CA19-9 (sialyl Lewis^a). Serum DU-PAN-2 and CA19-9 values of 17 EMACs were measured using an EIA kit and a RIA kit, respectively. The positive/negative cutoff values for both markers were set at the [mean+2xSD] from the serum values of 19 benign uterine cases as follows; DUPAN-2, 73.9 U/mL; CA19-9, 37.4 U/mL. Immunohistochemical expressions of DU-PAN-2 and CA19-9 in EMACs were analyzed, applying an indirect immunoperoxidase method. The Lewis blood group type was determined using the hemagglutination test. The serum elevations of DU-PAN-2 and CA19-9 higher than the cutoff values before surgery were noted in 29.4% (5/17) and 23.5% (4/17) of EMACs, respectively. Except for one patient who died of systemic tumor dissemination, the elevated serum values of DU-PAN-2 and CA19-9 declined to the levels lower than the cutoff values after surgery. The relationship between immunohistochemical profiles and serum values was statistically proven to be closer in DU-PAN-2 (r=0.609, p=0.0094) than in CA19-9 (r=0.326, p=0.2022). The Lewis negative patients among them were consistently negative for CA19-9 serologically. We believe that DU-PAN-2 could be clinically useful in EMACs as well as immunohistochemically and recommend that this be added into a panel of tumor markers for EMACs.
• ミネラル摂取による骨粗鬆症モデルマウスの骨代謝に及ぼす影響2022 · (一社)日本微量元素学会, 2022年09月, Biomedical Research on Trace Elements, 33(1) (1), 144 - 144, 日本語

• SLCトランスポーターの免疫組織化学染色による食道癌術前化学療法の効果予測 鴨志田 伸吾 日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 2020年04月 - 2023年03月, 研究代表者2020 · KUID parsed section
• VEGF依存性腫瘍血管の同定と大腸癌ベバシズマブ療法の効果予測 鴨志田 伸吾 学術研究助成基金助成金／基盤研究(C), 2016年04月 - 2019年03月, 研究代表者 競争的資金2016 · KUID parsed section
• 全身諸臓器の正常・腫瘍組織における細胞周期・細胞死関連蛋白の網羅的発現解析 新谷 路子 学術研究助成基金助成金／基盤研究(C), 2015年04月 - 2018年03月 競争的資金2015 · KUID parsed section
• SLCトランスポーター発現による胃癌化学療法の効果予測 鴨志田 伸吾 学術研究助成基金助成金／基盤研究(C), 2013年04月 - 2016年03月, 研究代表者 競争的資金2013 · KUID parsed section

• Official profile
• ORCID